383 related articles for article (PubMed ID: 33849094)
1. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.
Li P; Qin P; Fu X; Zhang G; Yan X; Zhang M; Zhang X; Yang J; Wang H; Ma Z
Ann Palliat Med; 2021 Mar; 10(3):3039-3049. PubMed ID: 33849094
[TBL] [Abstract][Full Text] [Related]
2. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
Front Immunol; 2022; 13():912180. PubMed ID: 35844502
[TBL] [Abstract][Full Text] [Related]
4. Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China.
Wang Y; Lu J; Wu C; Fei F; Chu Z; Lu P
Front Immunol; 2023; 14():1276107. PubMed ID: 38124739
[TBL] [Abstract][Full Text] [Related]
5. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
7. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
8. A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Xu X; Wang D; Chen W; Li N; Suwinski R; Rossi A; Rosell R; Zhong J; Fan Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4511-4525. PubMed ID: 35070757
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy.
Li H; Yu H; Lan S; Zhao D; Liu Y; Cheng Y
Technol Cancer Res Treat; 2021; 20():15330338211039948. PubMed ID: 34851203
[No Abstract] [Full Text] [Related]
10. Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry.
Ma W; Wei S; Long S; Tian EC; McLaughlin B; Jaimes M; Montoya DJ; Viswanath VR; Chien J; Zhang Q; Van Dyke JE; Chen S; Li T
Front Immunol; 2023; 14():1206631. PubMed ID: 37638022
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
12. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract][Full Text] [Related]
13. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
Ottonello S; Genova C; Cossu I; Fontana V; Rijavec E; Rossi G; Biello F; Dal Bello MG; Tagliamento M; Alama A; Coco S; Boccardo S; Vanni I; Ferlazzo G; Moretta L; Grossi F; Mingari MC; Carrega P; Pietra G
Front Immunol; 2020; 11():125. PubMed ID: 32117275
[TBL] [Abstract][Full Text] [Related]
14. [Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced
Non-small Cell Lung Cancer and Its Therapeutic Effect].
Wang Y; Wang Y; Jiang M; Zhao Y; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):182-187. PubMed ID: 33819968
[TBL] [Abstract][Full Text] [Related]
15. Peripheral CD4
Yang X; Li Q; Zeng T
Front Immunol; 2024; 15():1364507. PubMed ID: 38650951
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
Wang H; Huang H; Liu T; Chen Y; Li J; He M; Peng J; Liang E; Li J; Liu W
Front Immunol; 2024; 15():1325330. PubMed ID: 38404585
[TBL] [Abstract][Full Text] [Related]
17. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
[TBL] [Abstract][Full Text] [Related]
18. CD137
Gelibter A; Asquino A; Strigari L; Zizzari IG; Tuosto L; Scirocchi F; Pace A; Siringo M; Tramontano E; Bianchini S; Bellati F; Botticelli A; Paoli D; Santini D; Nuti M; Rughetti A; Napoletano C
J Transl Med; 2024 Apr; 22(1):329. PubMed ID: 38570798
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
